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Abstract
Breast cancer cell-response to inflammatory cytokines such as interleukin-6 (IL-6) and oncostatin M (OSM) may affect the
course of clinical disease in a cancer subtype-dependent manner. Furthermore, vascular endothelial growth factor A
(VEGF) secretion induced by IL-6 and OSM may also be subtype-dependent. Utilizing datasets from Oncomine, we show
that poor survival of invasive ductal carcinoma (IDC) breast cancer patients is correlated with both high VEGF expression
and high cytokine or cytokine receptor expression in tumors. Importantly, epidermal growth factor receptor-negative
(HER2-), but not HER2-positive (HER2+), patient survival is significantly lower with high tumor co-expression of VEGF and
OSM, OSMRβ, IL-6, or IL-6Rα compared to low co-expression. Furthermore, assessment of HER2- breast cancer cells in
vitro identified unique signaling differences regulating cytokine-induced VEGF secretion. The levels of VEGF secretion
were analyzed by ELISA with siRNAs for hypoxia inducible factor 1 α (HIF1α) and signal transducer and activator of
transcription 3 (STAT3). Specifically, we found that estrogen receptor-negative (ER-) MDA-MB-231 cells respond only to
OSM through STAT3 signaling, while ER+ T47D cells respond to both OSM and IL-6, though to IL-6 to a lesser extent.
Additionally, in the ER+ T47D cells, OSM signals through both STAT3 and HIF1α. These results highlight that the survival
of breast cancer patients with high co-expression of VEGF and IL-6 family cytokines is dependent on breast cancer
subtype. Thus, the heterogeneity of human breast cancer in relation to IL-6 family cytokines and VEGF may have
important implications in clinical treatment options, disease progression, and ultimately patient prognosis.
Translational Oncology (2019) 12, 245–255

Introduction
In the United States, breast cancer is the most frequently diagnosed
cancer among women [1]. With 268,670 new cases of invasive breast
cancer (IBC) expected for 2018, breast cancer remains a leading
public health concern, both in the United States and globally. One of
the main concerns is the complex relationship between IBC subtypes,
clinical treatment, and long-term survival [1,2]. In particular, antiangiogenic treatments for breast cancer have had variable clinical
success at best, and at worst, show no improvement in disease-free
survival [3]. The high level of clinical variability with anti-angiogenic
therapies may be due, in part, to the highly heterogeneous nature
of breast cancer and their subsequent biomarkers [4]. This underlies
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the need to improve our understanding of clinical outcomes in
conjunction with existing breast cancer subtype biomarkers such as
estrogen receptor (ER), progesterone receptor (PR), and epidermal
growth factor 2 (HER2).
Current breast cancer subtype classifications depend on the
evaluation of ER, PR, and HER2 [5]. The luminal A (ER+ PR+
HER2-; low Ki67) breast cancer subtype is the least aggressive, while
the luminal B (ER+ PR+ HER2-; high Ki67 or HER2+) breast cancer
subtype is more aggressive and has an overall poorer prognosis [5–7].
In contrast, cancers classified as basal-like triple negative breast
cancer (TNBC; ER- PR- HER2-) are highly aggressive with increased
probability of relapse and display unfavorable prognoses, in large part
due to the lack of targeted therapies available to treat this subtype
[4,8]. Similarly, HER2-type breast cancers (ER- PR- HER2+) also
have poor prognoses [9]. While superficial differences between the
subtypes are relatively well known, the specific molecular mechanisms
that drive these differences remain elusive. Specifically, increased
inflammatory markers in the serum of breast cancer patients appear to
be associated with poor prognosis [10].
Inflammatory cytokines of the interleukin-6 (IL-6) family,
including IL-6 and oncostatin M (OSM), have been implicated in
the migration and invasiveness of human breast cancer cells [11–13],
while leukemia inhibitory factor (LIF) has been shown to act as a
tumor/metastasis suppressor [14–17]. Moreover, both IL-6 and OSM
have been shown to be capable of directly and indirectly driving
angiogenesis [18–20]. Receptor complexes of the IL-6 family all
consist of at least one molecule of glycoprotein 130 (gp130), as well
as subunit(s) specific to their respective receptor [21,22]. Following
IL-6 or OSM ligand binding, the gp130 receptor complexes
activate the JAK/STAT, MAPK, PI3K/AKT, and JNK pathways,
thereby mediating transcription of target genes [22–27]. Although IL-6
and LIF bind specifically to their individual receptors (IL-6R and LIFR,
respectively), OSM is capable of binding to both the LIFR and
the OSM receptor (OSMR), which it binds to with higher affinity
[28–30]. The resultant cytokine signaling cascades play various roles
in the progression of breast cancer through activation of target
genes involved in differentiation, survival, apoptosis, and angiogenesis
[26,31,32].
Normal angiogenesis is maintained in homeostasis by numerous proand anti-angiogenic factors, resulting in a normal rate of blood vessel
growth [33]. During tumor angiogenesis, both tumor cells and tumorassociated stromal/immune cells secrete proangiogenic factors [27,34].
The most potent proangiogenic factor, vascular endothelial growth factor
A (VEGF), promotes the survival, proliferation, and motility of
endothelial cells and enhances vascular permeability [35,36]. Regulation
of VEGF expression typically depends on hypoxia-driven signaling
through the binding of the dimeric transcription factor hypoxia-inducible
factor 1 (HIF1) [HIF1α + HIF1β] to the hypoxia response element
(HRE) in the VEGF promoter. [37]. However, activation of transcription
factor binding to sites other than the HRE, such as those for signal
transducer and activator of transcription-3 (STAT3), allow transcription
to be activated independently of hypoxia [38–41]. While it has been
shown that hypoxia can induce STAT3 phosphorylation [42,43],
hypoxia-induced pSTAT3 is not rapid. Therefore, cellular hypoxia likely
promotes the secretion of cytokines from breast tumor cells that then
promote STAT3 phosphorylation. In fact, hypoxia has been shown to
increase production of cytokines such as IL-6, IL-1α, and IL-1β, which
are all known to activate STAT3 signaling [44,45]. Even under nonhypoxic conditions, IL-6 family cytokines have been shown to promote
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VEGF expression via activation of transcription factors HIF1α and
STAT3 [19,27,46,47].
In this paper, we study the differential effects of the inflammatory
interleukin-6 (IL-6)-family cytokines on breast cancer patient outcomes,
as well as the induction of vascular endothelial growth factor A (VEGF) in
a breast cancer subtype-specific manner. Using collated Oncomine data,
we systemically explored the co-expression of VEGF with inflammatory
cytokine components among invasive ductal carcinoma (IDC) patients
subdivided by HER2- or HER2+ status. Importantly, we found that
HER2- patient survival significantly decreases when breast tumors coexpress high levels of VEGF and high levels of OSM, OSMRβ, IL-6, or
IL-6Rα. Conversely, in patients with HER2+ disease, co-expression of
VEGF and these inflammatory proteins had little to no effect on survival.
We also show that regulation of IL-6-family cytokine-induced VEGF in
HER2- cells differ between ER+ and ER- breast cancer cells. This study
highlights the breast cancer subtype-specific differences in cytokine
signaling that lead to VEGF secretion, and importantly, the potential for
therapeutic suppression of IL-6 family cytokines in HER2- breast cancer.
Materials and Methods

Oncomine Analysis
We utilized the Curtis Breast human mRNA microarray dataset from
Oncomine (Compendia Bioscience, Ann Arbor, MI) to assess correlations
between inflammatory cytokines and VEGF. The constraints used to
define the dataset used were “Invasive Ductal Carcinoma” and a detailed
survival status of either “Alive” or “Dead of Disease.” The resultant dataset
was used to calculate quartiles. From these, the upper quartile (N75th
percentile) and lower quartile (b25th percentile) were selected for
comparison in order to clearly depict survival trends that may have been
otherwise muddled by use of all quartile combinations. For co-expression
analysis, we calculated survival curves using patients in the upper quartile
of both VEGF and each particular IL-6 family gene (“high/high”) and
the lower quartile of both (“low/low”). Statistical analyses between
survival of two groups was calculated using a log-rank test in GraphPad
Prism 5 software *P b .05, **P b .01, ***P b .001.

Tissue Culture
Triple negative MDA-MB-231, luminal A T47D, and triple positive
BT474 human breast cancer cells (ATCC) were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS), 1%
penicillin streptomycin, and 1% sodium pyruvate and incubated at 37 °C
at 5% CO2. HER2+ SK-BR-3 human breast cancer cells were grown in
McCoy's 5A medium, while MDA-MB-453 human breast cancer cells
were grown in DMEM with the same supplements as above. Cytokine
treatments, in low serum media (1% FBS) at 25 ng/mL, included
recombinant human OSM (Cat#300-10 T, Peprotech), IL-6 (Cat
#200–06, Peprotech), and LIF (Cat# 300–05, Peprotech) for the
indicated time points.

siRNA Transfection
siRNA pools targeting HIF1α, STAT3, JNK1, and JNK2 were
obtained from Dharmacon. In brief, 300,000 cells/well were plated in a
6-well plate, and siRNAs were transfected according to the Fast-Forward
protocol as outlined by the manufacturer of Hyperfect siRNA
Transfection Reagent (Cat# 301705, Qiagen). STAT3 siRNAs were
used at 25 nM, and cells were transfected for 72 hours and then treated
with OSM for 48 hours. HIF1α, JNK1, and JNK2 siRNAs were used at
concentrations of 20 nM, and were transfected for 24 hours prior to OSM
treatment. Knockdown was assessed via immunoblot analysis (see below).
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Immunoblot Analysis
Cells were lysed on ice with 1x RIPA buffer containing 1x protease
inhibitor cocktail (Cat# P8340, Sigma Aldrich). Lysates were run on
an SDS-PAGE gel, transferred onto a nitrocellulose membrane, and
blocked overnight in 5% non-fat dry milk in PBS containing 0.05%
Tween 20. Membranes were incubated overnight with primary
antibodies for HIF1α (Dilution: 1:1000 Cat# AF1935, R&D Systems),
STAT3 (Cat# 9132), p-STAT3 (Cat# 9145), JNK1 (Cat# 3708),
p-JNK1 (Cat# 4668), or β-Actin (Cat# 3700) ((1:1000, Cell Signaling
Technologies) in 5% NFDM-PBST. Membranes were washed with
PBST and incubated with HRP secondary antibody (Cat# 705–035003 Jackson ImmunoResearch) in 5% NFDM-PBST for 45 minutes,
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developed with ECL, and imaged on X-ray film on a Kodak 4000R
Image Station.

VEGF ELISA
Analysis of VEGF secretion in the conditioned media (CM) of
MDA-MB-231, T47D, MCF7, SK-BR-3, MDA-MB-453, and
BT474 (ATCC, Manassas, VA) breast cancer cells was assessed via
VEGF ELISA according to the manufacturer's protocol (Cat# Dy293B,
R&D Systems, Bethesda, MD). Cells were plated at a confluency of
50,000 or 100,000 cells in a 24-well plate and allowed to adhere
overnight. The following day, cells were serum-starved in serum free
media for 6 hours and treated with cytokines for the indicated time.

Figure 1. Inflammatory cytokine and VEGF co-expression are correlated with decreased survival of invasive ductal carcinoma patient.
These Kaplan–Meier curves in Figure 1, A and B, are a subset of the data presented in Supplemental Figure S1. A) Kaplan–Meier survival
curves of invasive ductal breast carcinoma patients with high OSM and VEGF expression (upper quartiles, respectively) present
diminished survival when compared to individuals with low OSM and VEGF expression (lower quartiles, respectively). Comparable trends
appear upon examination of the upper and lower quartiles of patients with B) OSMRβ and VEGF expression, C) IL-6 and VEGF expression,
and D) IL-6Rα and VEGF expression, indicating significant differences between upper and lower quartile survival for each group. Survival
of patients with invasive ductal breast carcinoma by E) LIF and VEGF expression and F) LIFRβ and VEGF expression are not significantly
different. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test *P b .05, **P b .01, ***P b .001.
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pSTAT3 ELISA
Intracellular pSTAT3 levels were assessed by ELISA, in accordance
with the manufacturer's protocol (Cat#7146, Cell Signaling). 50,000
cells were adhered to 24-well plates overnight in serum-free media.
Cells were incubated for the indicated times, and cell lysates were
collected using 1x Cell Lysis Buffer (Cat# 9803, Cell Signaling). The
lysates were diluted 1:3 with blocking buffer (PBS-0.05% Tween 20,
1% IgG-free BSA) and assessed by ELISA.

Statistical Analysis
All statistical analyses were performed using GraphPad Prism 5
software. To compare multiple groups, one- or two-way analysis of
variance were run with Tukey's and Bonferroni's post-test,
respectively where appropriate on ELISA data. Experiments were
considered statistically significant if p values were less than 0.05. Error
bars represent mean ± S.E. Experiments were performed at least three
times to determine statistical significance.
Results
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obtained from Oncomine [48], co-expression in IDC patients
was compared to survival and quantified by individual quartiles, as
demonstrated for OSM and VEGF (Figure S1A) and OSMRβ and
VEGF (Figure S1B). Utilizing just the upper and lower quartiles, we
observed a significant correlation between high co-expression of OSM
and VEGF and decreased survival, relative to low expression of both
OSM and VEGF (P = .0190, Figure 1A). Similarly, decreased survival
was observed in patients who had high expression levels of OSMRβ
and VEGF (P = .0012, Figure 1B), IL-6 and VEGF (P = .0005,
Figure 1C), or IL-6Rα and VEGF (P = .0016, Figure 1D) relative to
those with low co-expression of each respective gene pair. Patient
survival was not statistically affected by co-expression levels of LIF
and VEGF (P = .0578, Figure 1E) or LIFRβ and VEGF (P = .1020,
Figure 1F). Together, these results highlight the importance of tumor
cell co-expression of VEGF with OSM, OSMRβ, IL-6, or IL-6Rα on
the poor survival of individuals with IDC.

HER2- Status Dictates Poor Survival in IDC Patients with High
Co-Expression of OSM, IL-6, OSMRβ or IL-6Rα and VEGF

Inflammatory Cytokine and VEGF Co-Expression is Correlated As published studies have demonstrated the importance of receptor
status in breast cancer recurrence and treatment [48–50], we next
with Decreased Survival of IDC Patients
To address the clinical importance of IL-6 family cytokines in invasive
ductal carcinoma (IDC), we correlated patient survival relative to
expression levels of VEGF with OSM, IL-6, LIF, or their specific
receptor subunits. Using the Curtis METABRIC Breast dataset (47)

analyzed HER2 status on the survival of IDC patients according to
VEGF and IL-6 family molecule co-expression. A statistically significant
decrease in survival was only observed in HER2- patients with high
OSM and VEGF expression (P = .0016) and not in HER2+ patients

Figure 2. Co-expression of VEGF with OSM or OSMRβ appears to affect survival in HER2- but not HER2+ subtypes. A) Kaplan–Meier
survival curves of invasive ductal breast carcinoma for HER2- patients and HER2+ patients by OSM and VEGF expression. In HER2patients, high OSM and high VEGF expression (upper quartiles, respectively) is strongly correlated with decreased survival when
compared to patients with low OSM and low VEGF expression (lower quartiles, respectively). However, this trend is not evident in HER2+
individuals, as no significant difference is observed between survival of patients with OSM and VEGF expression in upper and lower
quartiles, respectively. Similar trends are observed in Kaplan–Meier survival curves for B) HER2- and HER2+ by OSMRβ and VEGF
expression. Analysis obtained from Oncomine dataset entitled Curtis Breast. Log-rank test *P b .05, **P b .01, ***P b .001.
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(P = .5963, Figure 2A). Decreased survival was also seen in HER2individuals with high OSMRβ and VEGF co-expression (P = .0001,
Figure 2B), high IL-6 and VEGF co-expression (P = .0005, Figure S2A),
and high IL-6Rα and VEGF co-expression (P = .0112; Figure S2B). No
statistically significant change in survival was detected with the respective
HER2+ individuals (High OSMRβ/VEGF, P = .9317, Figure 2B)
(High IL-6/VEGF, P = .6106, Figure S2A) (High IL-6Rα/VEGF,
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P = .0671, Figure S2B). High expression of LIF with high expression of
VEGF also was correlated with poor survival in HER2- (P b .0001,
Figure S2C), but not HER2+ IDC patients (P = .2806 Figure S2C).
However, no association between HER2 status and survival was
observed in IDC patients expressing high levels of LIFRβ and VEGF
(P = .1247 and P = .534, respectively, Figure S2D). The effect of
estrogen receptor (ER) status on patient survival was also investigated.

Figure 3. IL-6 family cytokine OSM induces VEGF secretion independent of HIF1α signaling in MDA-MB-231 cells. A) Treatment with
OSM, IL-6, and LIF (25 ng/mL) for 24 hours promotes expression of HIF1α in MDA-MB-231 TNBC cells. Addition of an siRNA targeting
HIF1α (siHIF1α) ablates the effect of adding cytokines. B) T47D cells treated with IL-6 family cytokines for 72 hours express greater levels
of HIF1α relative to non-treated control. Treatment with siHIF1α reduces this effect, as assessed by immunoblot analysis. Immunoblots
are representative of at least 3 experiments. Induction of VEGF secretion is observed following treatment with IL-6 family cytokines
(25 ng/mL) for 24 hours in C) MDA-MB-231 cells (n = 5) and for 72 hours in D) T47D cells (n = 3), as determined by ELISA. Treatment with
siHIF1α does not affect VEGF secretion in OSM-treated MDA-MB-231 cells; however, VEGF secretion is modestly reduced in T47D cells
treated with OSM and siHIF1α. E) A panel of additional human breast cancer cell lines were tested for VEGF expression by ELISA. HER2MCF7 cells have significant OSM-induced VEGF secretion, while HER2+ BT474, SK-BR-3, and MDA-MB-453 cells do not produce
increased VEGF in response to OSM. One-way ANOVA, Tukey's post-test, **P b .01, ***P b .001.
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In HER2- IDC patients, high co-expression of OSM and VEGF in ER+
patients was associated with poor survival (P = .0008), while ER- status
had no effect on survival (P = .6998, Figure S3A, B). ER status played a
less significant role in patient survival when HER2 status was associated
high OSMRβ and VEGF co-expression (Figure S3, C and D). These
data suggest that while ER+ HER2- patients typically have fair
prognoses [51], high tumor co-expression of OSM and VEGF
negatively impacts survival in these individuals.

OSM Promotes VEGF Secretion from HER2- Breast Cancer
Cells in a HIF1α Differential Manner

Translational Oncology Vol. 12, No. 2, 2019

MB-231 cells treated with siHIF1α and OSM, while this same treatment
reduced VEGF secretion by nearly 50% in T47D cells, demonstrating
different signaling mechanisms. To confirm the importance of HER2status on OSM-induced VEGF secretion, additional human breast cancer
cells were investigated. A 3.3-fold increase in VEGF secretion was seen
with ER+ HER2- MCF7 cells after a 72-hour treatment with OSM, as
compared to untreated controls (Figure 3E). Importantly, in HER2+
BT474 (ER+), SK-BR-3 (ER-), and MDA-MB-453 (ER-) cells [20,52],
OSM did not induce VEGF secretion (Figure 3E), despite the presence of
OSMRβ in all cell lines (Figure S4A). Together, this data suggests that
OSM-induced VEGF induction is likely mediated through different
pathways in ER+ versus ER- HER2- cells.
To confirm a functional effect for OSM-induced VEGF production,
we performed in vitro and in vivo angiogenesis assays. Conditioned
media (CM) from MDA-MB-231 cells treated with OSM induced
endothelial cell tube and branch point formation in human umbilical
vein endothelial cells (Figure S5, A and B). Similarly, CM from OSMtreated MDA-MB-231 cells had a 12-fold increase in angiogenesis, as
compared to CM from untreated MDA-MB-231 cells when mixed with
Matrigel and inserted into athymic nude mice (P b .001, Figure S5, C
and D). Together, these results suggest that OSM promotes the secretion
of functional VEGF from breast cancer cells.

Our data suggested that, high OSM co-expression with the
proangiogenic factor VEGF resulted in poor HER2- patient survival.
To study VEGF expression and its transcription factor, HIF1α, in
relation to IL-6 family cytokines, we used two distinct HER2- cell lines
with differing ER status, the ER-negative MDA-MB-231 (ER- PRHER2-) TNBC cell line and the ER-positive T47D (ER+ PR+ HER2-)
cell line.
Treatment with OSM, IL-6, or LIF (25 ng/mL) induced HIF1α
expression by western blot analysis in MDA-MB-231 cells at 24 hours
and in T47D cells at 72 hours, relative to non-treated cells (Figure 3, A
and B). These time points were selected as they were determined to have
maximal HIF1α-induction in each cell line (data not shown). Despite
the induction of HIF1α, treatment with IL-6 or LIF did not produce a OSM Strongly Induces STAT3 Activation in ER+ and ER- HER2significant change in the level of VEGF secreted (Figure 3, C and D). Breast Cancer Cells
On the other hand, OSM treatment accounted for a 3-fold increase in OSM is capable of binding to and activating both the OSMR and the
VEGF secretion by ELISA in MDA-MB-231 cells at 24 hours (P b .05) LIFR, while LIF binds to only the LIFR and IL-6 binds to the IL-6
and an almost 4-fold increase in T47D cells at 72 hours (P b .001) receptor. Stimulation of these receptors activate various signaling
(Figure 3, C and D). Relative VEGF secretion was not altered in MDA- pathways including the STAT3 and JNK pathways [53–56]. First, we

Figure 4. OSM strongly induces phosphorylation of STAT3. A) Treatment with OSM (25 ng/mL) for 15 minutes, 30 minutes, and 1 hour
strongly induces phosphorylation of STAT3 (Tyr 705) in MDA-MB-231 cells and moderately induces JNK phosphorylation (T183/Y185).
Treatment with either IL-6 or LIF (25 ng/mL) does not induce pSTAT3 or pJNK. B) Treatment with OSM induces phosphorylation of STAT3 and
JNK in T47D cells. IL-6 induces moderate phosphorylation of STAT3 and JNK at early time points. Phosphorylation of STAT3 and JNK was
compared to control β-actin, as assessed by immunoblot analysis. Blots are representative of three experiments. Time course experiment for
STAT3 phosphorylation upon treatment with OSM or IL-6 (25 ng/mL) for 0.25–72 hours in C) MDA-MB-231 cells, and in D) T47D cells.
Treatment with IL-6 does not induce pSTAT3 expression in MDA-MB-231 cells, while inducing moderate pSTAT3 expression in T47D cells.
ELISA was performed in quadruplicate; two-way ANOVA with Bonferroni post-test, *P b .05, **P b .01, ***P b .001.
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confirmed that these receptor elements (OSMRβ, LIFRβ, IL-6Rα, and Activation of STAT3 Signaling is Required for VEGF Secretion
gp130) were expressed in MDA-MB-231 and T47D cells by RT-PCR by MDA-MB-231 TNBC Cells
(Figure S4B). Next, we sought to determine the mechanism by which Our data suggest that OSM-induced VEGF is independent of HIF1α in
OSM induces the expression of VEGF by investigating the activation of MDA-MB-231 TNBC cells. To determine whether OSM promotes
the transcription factors STAT3 and JNK, found downstream of OSMR. VEGF secretion via the STAT3 pathway, we performed VEGF ELISAs
Treatment with OSM (25 ng/mL) strongly induced phosphorylation using siRNAs targeting STAT3 (siSTAT3) and JNK1 and 2 (siJNK1
of STAT3 (pSTAT3) in MDA-MB-231 TNBC cells at both 15 and and siJNK2). In MDA-MB-231 cells, treatment with OSM and
30 minutes, as assessed by immunoblot. In contrast, addition of OSM siSTAT3 suppressed VEGF secretion (Figure 5A). However, this
only slightly induced phosphorylation of JNK1 (pJNK1) in these cells complete suppression was not observed in T47D cells, likely due to the
(Figure 4A). Neither the addition of IL-6 nor LIF led to STAT3 or role of HIF1α in the secretion of VEGF in this cell line (Figure 5B).
JNK1 phosphorylation in ER- MDA-MB-231 cells. In T47D cells, While initial studies using a chemical inhibitor of JNK suggested
stimulation with either OSM or IL-6 promoted phosphorylation of that JNK signaling was in part necessary for OSM-mediated induction
STAT3 at 15 and 30 minutes (Figure 4B). Phosphorylation of STAT3 of VEGF (Figure S6A), further investigations revealed that these
was not induced in ER+ T47D cells treated with LIF. A slight induction effects might have resulted from the off-target suppression of STAT3
of JNK1 phosphorylation was observed following treatment with OSM phosphorylation (Figure S6B). However, siRNAs targeting both
in T47D cells, whereas IL-6 and LIF did not produce an effect. In both JNK1 and JNK2 (siJNK1 and siJNK2, respectively) had no effect on
cell lines, levels of OSM-induced STAT3 phosphorylation were the levels of VEGF secretion in MDA-MB-231 or T47D cells treated
transient yet sustained over time up to 72 hours, with preferential with OSM (Figure 5, C and D). Together, these results demonstrate
activation around 0.5 hours, relative to treatment with IL-6 (P b .001, that OSM-mediated induction of VEGF is dependent on STAT3 in
Figure 4, C and D). Interestingly, treatment with IL-6 has no observed MDA-MB-231 cells, while T47D cells utilize STAT3, HIF1α, and
effect on pSTAT3 levels in MDA-MB-231 cells and only induced possibly other pathways to promote VEGF production in response
moderate STAT3 phosphorylation in T47D cells.
to OSM.

Figure 5. OSM induces VEGF via STAT3 signaling. A) Treatment with OSM (25 ng/mL) and siSTAT3 suppresses VEGF secretion by 3-fold
in MDA-MB-231 cells. B) Treatment with OSM and siSTAT3 moderately reduces VEGF secretion by T47D cells. VEGF secretion was not
reduced by the addition of siRNAs targeting both JNK1 and JNK2 in either C) MDA-MB-231 or D) T47D cells. Experiments were performed
in triplicate two-way ANOVA with Bonferroni post-test, *P b .05, ***P b .001.
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Discussion
The different subtype-specific molecular characteristics of human
breast cancer have important implications for clinical treatment
options, disease progression, and ultimately patient prognosis. In this
study, we show the correlation of high tumor cell co-expression of
VEGF with inflammatory cytokines (OSM and IL-6), or their
respective receptors (OSMRβ and IL-6Rα), with the poor survival of
individuals with HER2- invasive ductal carcinoma. This may be
caused by the fact that OSM, IL-6, and their receptors are associated
with increased metastatic capacity [57,58], including increased
invasion and migration [20,24,25,29,59] and the promotion of
angiogenesis [26,27,31,60]. Moreover, OSM has been shown to bind
to extracellular matrix proteins such as collagens, laminins, and
fibronectins in an active conformation; thereby, accumulating in a
breast tumor microenvironment to further promote these effects
[60,61]. Subsequently, we demonstrate that OSM induces VEGF in
HER2-, but not HER2+, breast cancer cells and that ER+ and ERHER2- tumor cells respond differently to IL-6 cytokines in their
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induction of VEGF. Together, our findings suggest that VEGF, OSM,
and IL-6 or their receptors can be used as potential negative prognostic
markers and therapeutic targets for breast cancer.
Our clinical analysis for this work included 1245 IDC patients
subdivided by HER2 and ER status. When IDC patients were
subdivided by HER2 status, a marked decrease in overall survival was
found in HER2- patients exhibiting high OSM or OSMRβ and VEGF
co-expression compared to HER2+ patients. HER2- patients also fared
much worse when their tumors had high co-expression of IL-6 or IL-6Rα
and VEGF. This data demonstrate clear statistical significance for breast
cancer patients with HER2-, but not HER2+ status. This was further
supported by our in vitro analyses showing that untreated HER2+
BT474 breast cancer cells constitutively express a basal level of VEGF
[62] and that OSM had no additional effect on the induction of VEGF
secretion in HER2+ cells such as BT474, SK-BR-3, and MDA-MB-453.
These findings may suggest redundancy between HER2 and inflammatory cytokine-induced signaling, with most IDC tumors requiring
overactivation of only one or the other pathway. Other studies show that,

Figure 6. Mechanistically distinct regulation of VEGF secretion in MDA-MB-231 TNBC and T47D (ER+/PR+/HER2-) cells. A) The VEGF
promoter can be activated by various transcription factors. B) In MDA-MB-231 cells, OSM mediates VEGF secretion by activating the
STAT3 signaling pathway downstream of the OSMR (OSMRβ + gp130). In T47D cells, OSM regulates VEGF secretion via both HIF1α and
the STAT3 signaling pathway.
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IL-6 family cytokines have been proposed as profiling markers for HER2breast cancer, specifically TNBC, while having no significant correlation
with HER2+ breast cancer [37]. Overall, these results indicate that the
inflammatory cytokines OSM and IL-6 contribute to the aggressive
phenotype seen with HER2- disease.
When investigating clinical IDC patient data with respect to ER
status, we were able to observe a significant negative effect on survival in
ER+/HER2- individuals with high co-expression of VEGF and OSM or
OSMRβ. This is interesting in light of the fact that OSM has been shown
to negatively regulate expression of the estrogen receptor itself [61]. Such
regulation may indicate a key element in OSM-driven malignancy, with
the possibility that ER+ tumor cells lose ER status over time and evolve to
become less susceptible to hormone therapies and more difficult to treat
[61]. Furthermore, several in vitro studies have demonstrated that OSM
has a greater effect inducing epithelial-mesenchymal transition (EMT)
and tumor cell detachment effects in ER+ PR+ HER2- breast cancer cell
lines, such as T47D and MCF7, than on ER- TNBCs like MDA-MB231 or MDA-MB-468 ([27,63,64]; data not shown).
Standing alone, these results suggest important differences between
breast cancer subtypes in relation to VEGF and IL-6 family inflammatory
cytokines. As our patient data suggest that high coexpression of IL-6
family cytokines and VEGF levels leads to poor survival in HER2- breast
cancer, we investigated two HER2- breast cancer cell lines: ER- MDAMB-231 and ER+ T47D. In normal physiological conditions, VEGF
expression is regulated under both hypoxic and non-hypoxic conditions,
as the promoter region contains several response elements, including an
hypoxia response element (HRE) for HIF1, that allow for VEGF
regulation downstream of various signaling pathways (Figure 6A,
[38–41]). Our studies showed that OSM, IL-6, and LIF each increased
expression of HIF1α, an important transcription factor for VEGF,
but only OSM had a significant effect on VEGF production levels.
Additionally, there were key differences in the signaling pathways
inducing VEGF secretion. Specifically, we showed that T47D cells utilize
STAT3, HIF1α, and possibly other pathways, while MDA-MB-231
cells relied solely on STAT3 activation for OSM-induced VEGF
secretion. (Figure 6B). In T47D cells, it is possible that STAT3 and
HIF1α directly interact with each other to induce VEGF. Pawlus et al.
demonstrated that STAT3 and HIF1α immunoprecipitate together in
breast cancer cells and may have synergistic effects when both pathways
are activated [41]. Additionally, suppression of HIF1 signaling by HIF1α
siRNA did not decrease hypoxia-induced STAT3 phosphorylation,
which suggests that STAT3 activation is not dependent on HIF1
signaling [65]. Together, these results may indicate unique properties
pertaining to angiogenic signaling in ER- TNBC versus ER+ PR+ HER2tumors.
Interestingly, although it might be expected that IL-6 should also
induce VEGF secretion from breast cancer cells, we found that in ERMDA-MB-231 cells, IL-6 did not activate the STAT3 pathway and
therefore did not promote VEGF secretion. Previous studies have
shown that IL-6 has no effect on some markers of metastatic fitness
such as E-cadherin levels in MDA-MB-231 cells, which are signaled
through the JAK/STAT3 pathway [66]. This suggests that while ERMDA-MB-231 cells express the IL-6 receptor, STAT3 signaling is
not necessarily regulated by IL-6 in these cells. While we showed that
IL-6 weakly activated the STAT3 pathway in ER+ T47D cells, this
induction was only seen in the first hour of treatment and did not
extend to 48 hours as did OSM-induced pSTAT3. Overall, the
activation of STAT3 signaling by OSM is significantly greater than
with IL-6 and highlights a difference in signaling magnitude and
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possibly a key functional distinction between these two cytokines in a
breast cancer subtype-specific manner.
Taken together, our studies demonstrate that co-expression of VEGF
and IL-6 family cytokine molecules emerge as potential negative
prognostic markers particularly for HER2-, but not HER2+, invasive
ductal breast carcinoma. Our follow-up in vitro experiments demonstrate distinct differential cytokine-induced STAT3 and HIF1α
signaling, which lead to varied levels of VEGF secretion among various
TNBC and ER+ PR+ HER2- breast tumor cells. These breast cancer
subtype-specific differences in HIF1α signaling could complicate anticancer therapies targeting HIF1, which are currently undergoing clinical
trials [67]. Collectively, these results suggest that therapeutic inhibition
of IL-6-family cytokines such as OSM may lead to VEGF suppression
and improved patient survival in HER2- disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2018.10.004.
Acknowledgements
Authors wish to thank Laura Bond for assistance with statistical analysis,
the Boise State University Biomolecular Research Center (BRC) and its
personnel, Dr. Juhi Ojha for discussion on clinical relevance, Kencee
Amyx for help with counting branch points, and the Department of
Veterans Affairs Medical Center, Boise ID, for its animal facility.
Conflict of Interest
The authors declare that they have no conflicts of interest.
Author's Contributions
All authors contributed substantially to the concept of the paper and
work presented in this study. Ken Tawara designed and ran the
experiments for Figures 4, D and E, and 5, and Figure S5, interpreted
the data, constructed Figure 6, and helped write and made substantial
edits to the manuscript. Hannah Scott and Jacqueline Emathinger
helped collect and interpret data from Oncomine for Figures 1 and 2
and Figure S1-S3, and also helped write the manuscript with help from
Danielle Hedeen and Madhuri Nandakumar. They also helped with the
conceptual design for Figure 6. Alex Ide contributed to data in Figure
S5, and Andrew Older contributed to data in Figure S5. Ryan Fox
contributed to data for Figures 3 and 4, B and C, Daniel Greiner
contributed to data in Figure 3 and Figure S4A, and Dollie LaJoie
contributed to the data for Figure S4B. Ryan Holzer contributed initial
conceptual guidance and preliminary data for the overall concept of the
paper. Cheryl Jorcyk, who as the principal investigator, provided
conceptual guidance for all aspects of the project.
References
[1] Society AC (2018). In: American Cancer Society I, editor. Cancer Facts and
Figures 2018. p. 1–76 [Atlanta].
[2] Society AC (2018). Breast Cancer Facts and Figures 2017–2018. Atlanta:
American Cancer Society, Inc.
[3] Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, Warnke E, and
Magnusson NE (2014). Anti-vascular endothelial growth factor therapy in breast
cancer. Int J Mol Sci 15(12), 23024–23041. https://doi.org/10.3390/ijms151223024
[Epub 2014/12/11. PubMed PMID: 25514409; PMCID: PMC4284752].
[4] Anderson WF, Rosenberg PS, Prat A, Perou CM, and Sherman ME (2014).
How many etiological subtypes of breast cancer: two, three, four, or more? J Natl
Cancer Ins 106(8), 1–11 [Epub August 12, 2014].
[5] Society AC (2015). Breast Cancer Facts and Figures 2015–2016. Atlanta:
American Cancer Society, Inc.
[6] Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen
MB, van de Rijn M, and Jeffrey SS, et al (2001). Gene expression patterns of

254

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

Differential VEGF Secretion in HER2- Breast Cancer

Tawara et al.

breast carcinomas distinguish tumor subclasses with clinical implications. Proc
Natl Acad Sci U S A 98(19), 10869–10874. https://doi.org/10.1073/
pnas.191367098 [PubMed PMID: 11553815; PMCID: PMC58566].
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, and
Perou CM (2006). Concordance among gene-expression-based predictors for
breast cancer. N Engl J Med 355(6), 560–569. https://doi.org/10.1056/
NEJMoa052933 [PubMed PMID: 16899776].
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW,
Sartor CI, Graham ML, and Perou CM (2007). The triple negative paradox:
primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8),
2329–2334. https://doi.org/10.1158/1078-0432.CCR-06-1109 [PubMed
PMID: 17438091].
Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, and Yano T (2017).
Comparison of the prognostic values of preoperative inflammation-based parameters
in patients with breast cancer. PLoS One 12(5)e0177137. https://doi.org/10.1371/
journal.pone.0177137 [Epub 2017/05/10. PubMed PMID: 28489884].
Walter M, Liang S, Ghosh S, Hornsby PJ, and Li R (2009). Interleukin 6
secreted from adipose stromal cells promotes migration and invasion of breast
cancer cells. Oncogene 28(30), 2745–2755. https://doi.org/10.1038/
onc.2009.130 [PubMed PMID: 19483720; PMCID: 2806057].
Bolin C, Tawara K, Sutherland C, Redshaw J, Aranda P, Moselhy J, Anderson R, and
Jorcyk CL (2012). Oncostatin m promotes mammary tumor metastasis to bone and
osteolytic bone degradation. Genes Cancer 3(2), 117–130. https://doi.
org/10.1177/1947601912458284 [PubMed PMID: 23050044; PMCID:
PMC3463924].
Jorcyk CL, Holzer RG, and Ryan RE (2006). Oncostatin M induces cell detachment
and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine
33(6), 323–336. https://doi.org/10.1016/j.cyto.2006.03.004.
Luo Q, Wang C, Jin G, Gu D, Wang N, Song J, Jin H, Hu F, Zhang Y, and Ge
T, et al (2015). LIFR functions as a metastasis suppressor in hepatocellular
carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Carcinogenesis 36(10), 1201–1212. https://doi.org/10.1093/carcin/bgv108
[PubMed PMID: 26249360].
Humbert L, Ghozlan M, Canaff L, Tian J, and Lebrun JJ (2015). The leukemia
inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in
human cutaneous melanoma. BMC Cancer 15, 200. https://doi.org/10.1186/
s12885-015-1177-1 [PubMed PMID: 25885043; PMCID: PMC4389797].
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S,
Liang H, Lin HK, and Hung MC, et al (2012). LIFR is a breast cancer metastasis
suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat
Med 18(10), 1511–1517. https://doi.org/10.1038/nm.2940 [PubMed PMID:
23001183; PMCID: PMC3684419].
García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, and Royuela M (2008).
OSM, LIF, its receptors, and its relationship with the malignance in human
breast carcinoma (in situ and in infiltrative). Cancer Invest 26(3), 222–229. https:
//doi.org/10.1080/07357900701638491 [PubMed PMID: 18317962].
Yang X, Lin A, Jiang N, Yan H, Ni Z, Qian J, and Fang W (2017). Interleukin-6
trans-signalling induces vascular endothelial growth factor synthesis partly via Janus
kinases-STAT3 pathway in human mesothelial cells. Nephrology (Carlton) 22(2),
150–158. https://doi.org/10.1111/nep.12746 [PubMed PMID: 26869278].
Vasse M, Pourtau J, Trochon V, Muraine M, Vannier JP, Lu H, Soria J, and
Soria C (1999). Oncostatin M induces angiogenesis in vitro and in vivo.
Arterioscler Thromb Vasc Biol 19(8), 1835–1842 [PubMed PMID: 10446061].
Winder DM, Chattopadhyay A, Muralidhar B, Bauer J, English WR, Zhang X,
Karagavriilidou K, Roberts I, Pett MR, and Murphy G, et al (2011).
Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma
cells is associated with a pro-angiogenic phenotype and increased cell motility and
invasiveness. J Pathol 225(3), 448–462 [PubMed PMID: 21952923].
Liu J, Hadjokas N, Mosley B, Estrov Z, Spence MJ, and Vestal RE (1998).
Oncostatin M-specific receptor expression and function in regulating cell
proliferation of normal and malignant mammary epithelial cells. Cytokine 10(4),
295–302. https://doi.org/10.1006/cyto.1997.0283 [S1043-4666(97)90283-0
[pii] PubMed PMID: 9617575].
Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K,
Taga T, and Kishimoto T (1993). IL-6-induced homodimerization of gp130 and
associated activation of a tyrosine kinase. Science 260(5115), 1808–1810 [PubMed
PMID: 8511589].
Boulanger MJ and Garcia KC (2004). Shared cytokine signaling receptors: structural
insights from the gp130 system. Adv Protein Chem 68, 107–146. https://doi.
org/10.1016/S0065-3233(04)68004-1 [PubMed PMID: 15500860].

Translational Oncology Vol. 12, No. 2, 2019

[23] Demyanets S, Huber K, and Wojta J (2012). Vascular effects of glycoprotein130
ligands–part I: pathophysiological role. Vascul Pharmacol 56(1–2), 34–46. https://
doi.org/10.1016/j.vph.2011.12.004 [PubMed PMID: 22197898].
[24] Hibi M, Nakajima K, and Hirano T (1996). IL-6 cytokine family and signal
transduction: a model of the cytokine system. J Mol Med (Berl) 74(1), 1–12
[PubMed PMID: 8834766].
[25] Li TM, Wu CM, Huang HC, Chou PC, Fong YC, and Tang CH (2012).
Interleukin-11 increases cell motility and up-regulates intercellular adhesion
molecule-1 expression in human chondrosarcoma cells. J Cell Biochem 113(11),
3353–3362. https://doi.org/10.1002/jcb.24211 [PubMed PMID: 22644863].
[26] Scheller J, Chalaris A, Schmidt-Arras D, and Rose-John S (2011). The pro- and
anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta
1813(5), 878–888. https://doi.org/10.1016/j.bbamcr.2011.01.034.
[27] Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, and Jorcyk CL (2005). Breast
cancer cells stimulate neutrophils to produce oncostatin M: Potential implications for
tumor progression. Cancer Res 65(19), 8896–8904. https://doi.org/10.1158/00085472.can-05-1734 [PubMed PMID: ISI:000232199400043].
[28] Fischer P and Hilfiker-Kleiner D (2007). Survival pathways in hypertrophy and
heart failure: the gp130-STAT axis. Basic Res Cardiol 102(5), 393–411 [PubMed
PMID: 17918316].
[29] Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, and
Schaper F (2003). Principles of interleukin (IL)-6-type cytokine signalling and its
regulation. Biochem J 374(Pt 1), 1–20. https://doi.org/10.1042/BJ20030407
[PubMed PMID: 12773095; PMCID: PMC1223585].
[30] Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L,
Churakova T, Travis M, and Vaisberg E, et al (2002). IL-27, a heterodimeric
cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T
cells. Immunity 16(6), 779–790 [PubMed PMID: 12121660].
[31] Scheller J, Grötzinger J, and Rose-John S (2006). Updating interleukin-6 classicand trans-signaling. Signal Transduct 6(4), 240–259. https://doi.org/10.1002/
sita.200600086.
[32] Kareva I, Abou-Slaybi A, Dodd O, Dashevsky O, and Klement GL (2016). Normal
wound healing and tumor angiogenesis as a game of competitive inhibition. PLoS
One 11(12), e0166655. https://doi.org/10.1371/journal.pone.0166655 [Epub
2016/12/09. PubMed PMID: 27935954; PMCID: PMC5147849].
[33] Hanahan D and Folkman J (1996). Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell 86(3), 353–364 [PubMed PMID:
8756718].
[34] Dvorak HF, Nagy JA, Feng D, Brown LF, and Dvorak AM (1999). Vascular
permeability factor/vascular endothelial growth factor and the significance of
microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol
237, 97–132 [PubMed PMID: 9893348].
[35] Ferrara N and Adamis AP (2016). Ten years of anti-vascular endothelial growth
factor therapy. Nat Rev Drug Discov 15(6), 385–403. https://doi.org/10.1038/
nrd.2015.17 [PubMed PMID: 26775688].
[36] Brat DJ, Kaur B, and Van Meir EG (2003). Genetic modulation of hypoxia
induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci
8, d100–d116 [Epub 2003/01/01. PubMed PMID: 12456339].
[37] Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T,
Sinibaldi D, and Coppola D, et al (2002). Constitutive Stat3 activity up-regulates
VEGF expression and tumor angiogenesis. Oncogene 21(13), 2000–2008. https://doi.
org/10.1038/sj.onc.1205260 [PubMed PMID: 11960372].
[38] Damert A, Ikeda E, and Risau W (1997). Activator-protein-1 binding
potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma
cells. Biochem J 327(Pt 2), 419–423 [PubMed PMID: 9359410; PMCID:
PMC1218810].
[39] Pang L, Zhang Y, Yu Y, and Zhang S (2013). Resistin promotes the expression of
vascular endothelial growth factor in ovary carcinoma cells. Int J Mol Sci 14(5),
9751–9766. https://doi.org/10.3390/ijms14059751 [PubMed PMID:
23652833; PMCID: PMC3676810].
[40] Sun D, Liu WJ, Guo K, Rusche JJ, Ebbinghaus S, Gokhale V, and Hurley LH
(2008). The proximal promoter region of the human vascular endothelial growth
factor gene has a G-quadruplex structure that can be targeted by G-quadruplexinteractive agents. Mol Cancer Ther 7(4), 880–889. https://doi.org/10.1158/15357163.MCT-07-2119 [PubMed PMID: 18413801; PMCID: PMC2367258].
[41] Pawlus MR, Wang L, and Hu CJ (2014). STAT3 and HIF1α cooperatively activate
HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 33(13),
1670–1679. https://doi.org/10.1038/onc.2013.115 [PubMed PMID: 23604114;
PMCID: PMC3868635].

Translational Oncology Vol. 12, No. 2, 2019

Differential VEGF Secretion in HER2- Breast Cancer

[42] Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, and Kuppusamy P
(2009). Hypoxia induces chemoresistance in ovarian cancer cells by activation of
signal transducer and activator of transcription 3. Int J Cancer 125(9), 2198–2204.
https://doi.org/10.1002/ijc.24601 [PubMed PMID: 19623660; PMCID:
PMC2893222].
[43] Naldini A, Carraro F, Silvestri S, and Bocci V (1997). Hypoxia affects cytokine
production and proliferative responses by human peripheral mononuclear cells.
J Cell Physiol 173(3), 335–342. https://doi.org/10.1002/(SICI)1097-4652
(199712)173:3b335::AID-JCP5N3.0.CO;2-O [PubMed PMID: 9369946].
[44] Benyo DF, Miles TM, and Conrad KP (1997). Hypoxia stimulates cytokine
production by villous explants from the human placenta. J Clin Endocrinol
Metab 82(5), 1582–1588. https://doi.org/10.1210/jcem.82.5.3916 [PubMed
PMID: 9141553].
[45] Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, and Levi BZ (1998).
Regulation of vascular endothelial growth factor (VEGF) expression is mediated by
internal initiation of translation and alternative initiation of transcription. Oncogene
17(2), 227–236. https://doi.org/10.1038/sj.onc.1202019 [PubMed PMID:
9674707].
[46] Weiss TW, Simak R, Kaun C, Rega G, Pflüger H, Maurer G, Huber K, and
Wojta J (2011). Oncostatin M and IL-6 induce u-PA and VEGF in prostate
cancer cells and correlate in vivo. Anticancer Res 31(10), 3273–3278 [PubMed
PMID: 21965736].
[47] Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D,
Lynch AG, Samarajiwa S, and Yuan Y, et al (2012). The genomic and
transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Nature 486(7403), 346–352. https://doi.org/10.1038/nature10983 [PubMed
PMID: 22522925; PMCID: PMC3440846].
[48] Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, and Kennecke H
(2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin
Oncol 28(10), 1684–1691. https://doi.org/10.1200/JCO.2009.24.9284
[PubMed PMID: 20194857].
[49] Lin J, Goldstein L, Nesbit A, and Chen MY (2015). Influence of Hormone
Receptor Status on Spinal Metastatic Lesions in Patients with Breast Cancer.
World Neurosurg. https://doi.org/10.1016/j.wneu.2015.07.068 [PubMed
PMID: 26260940].
[50] Knight WA, Osborne CK, Yochmowitz MG, and McGuire WL (1980). Steroid
hormone receptors in the management of human breast cancer. Ann Clin Res 12
(5), 202–207 [PubMed PMID: 7015982].
[51] Holliday DL and Speirs V (2011). Choosing the right cell line for breast cancer
research. Breast Cancer Res 13(4), 215. https://doi.org/10.1186/bcr2889 [Epub
2011/08/12. PubMed PMID: 21884641; PMCID: PMC3236329].
[52] Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung
MC, Bonfiglio T, and Hicks DG, et al (2010). The Expression Patterns of ER,
PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in
Breast Cancer Cell Lines. Breast Cancer (Auckl) 4, 35–41 [Epub 2010/05/20.
PubMed PMID: 20697531; PMCID: PMC2914277].
[53] Badache A and Hynes NE (2001). Interleukin 6 inhibits proliferation and, in
cooperation with an epidermal growth factor receptor autocrine loop, increases
migration of T47D breast cancer cells. Cancer Res 61(1), 383–391 [PubMed
PMID: 11196191].
[54] Korzus E, Nagase H, Rydell R, and Travis J (1997). The mitogen-activated
protein kinase and JAK-STAT signaling pathways are required for an oncostatin
M-responsive element-mediated activation of matrix metalloproteinase 1 gene
expression. J Biol Chem 272(2), 1188–1196 [PubMed PMID: 8995420].

Tawara et al.

255

[55] Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM,
Topley N, and Jones SA (2002). Secretion of oncostatin M by infiltrating
neutrophils: regulation of IL-6 and chemokine expression in human mesothelial
cells. J Immunol 169(9), 5244–5251 [PubMed PMID: 12391243].
[56] Song Z, Lin Y, Ye X, Feng C, Lu Y, Yang G, and Dong C (2016). Expression of IL-1α
and IL-6 is Associated with Progression and Prognosis of Human Cervical Cancer. Med
Sci Monit 22, 4475–4481 [PubMed PMID: 27866212; PMCID: PMC5120643].
[57] Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J, Theilen
T, Granitto S, and Zhang X, et al (2013). The IL-6/JAK/Stat3 feed-forward loop
drives tumorigenesis and metastasis. Neoplasia 15(7), 848–862 [PubMed PMID:
23814496; PMCID: PMC3689247].
[58] Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo
D, Wen Y, and Swanson KE, et al (2013). MicroRNA-30c inhibits human breast
tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun
4, 1393. https://doi.org/10.1038/ncomms2393 [PubMed PMID: 23340433;
PMCID: PMC3723106].
[59] Lewis VO, Ozawa MG, Deavers MT, Wang G, Shintani T, Arap W, and
Pasqualini R (2009). The interleukin-11 receptor alpha as a candidate liganddirected target in osteosarcoma: consistent data from cell lines, orthotopic
models, and human tumor samples. Cancer Res 69(5), 1995–1999. https://doi.
org/10.1158/0008-5472.CAN-08-4845 [PubMed PMID: 19244100].
[60] Ryan RE, Martin B, Mellor L, Jacob RB, Tawara K, McDougal OM, Oxford JT,
and Jorcyk CL (2015). Oncostatin M binds to extracellular matrix in a bioactive
conformation: implications for inflammation and metastasis. Cytokine 72(1),
71–85. https://doi.org/10.1016/j.cyto.2014.11.007 [PubMed PMID: 25622278;
PMCID: PMC4328881].
[61] West NR, Murphy LC, and Watson PH (2012). Oncostatin M suppresses
oestrogen receptor-α expression and is associated with poor outcome in human
breast cancer. Endocr Relat Cancer 19(2), 181–195. https://doi.org/10.1530/
ERC-11-0326 [PubMed PMID: 22267707].
[62] Bottai G, Diao L, Baggerly KA, Paladini L, Győrffy B, Raschioni C, Pusztai L, Calin
GA, and Santarpia L (2017). Integrated microRNA-mRNA profiling identifies
oncostatin M as a marker of mesenchymal-Like ER-negative/HER2-negative breast
cancer. Int J Mol Sci 18(1). https://doi.org/10.3390/ijms18010194 [Epub
2017/01/19. PubMed PMID: 28106823; PMCID: PMC5297825].
[63] Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, and Le XF (2006).
HER2 signaling modulates the equilibrium between pro- and antiangiogenic
factors via distinct pathways: implications for HER2-targeted antibody therapy.
Oncogene 25(52), 6986–6996. https://doi.org/10.1038/sj.onc.1209685 [Epub
2006/05/22. PubMed PMID: 16715132].
[64] Tawara K, Bolin C, Koncinsky J, Kadaba S, Covert H, Sutherland C, Bond L,
Kronz J, Garbow JR, and Jorcyk CL (2018). OSM potentiates preintravasation
events, increases CTC counts, and promotes breast cancer metastasis to the lung.
Breast Cancer Res 20(1), 53. https://doi.org/10.1186/s13058-018-0971-5
[PubMed PMID: 29898744; PMCID: 6001163].
[65] Asgeirsson KS, Olafsdóttir K, Jónasson JG, and Ogmundsdóttir HM (1998). The
effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 10
(9), 720–728. https://doi.org/10.1006/cyto.1998.0349 [PubMed PMID: 9770334].
[66] Malinda KM (2009). In vivo matrigel migration and angiogenesis assay. Methods
Mol Biol 467, 287–294. https://doi.org/10.1007/978-1-59745-241-0_17
[PubMed PMID: 19301678].
[67] Yu T, Tang B, and Sun X (2017). Development of inhibitors targeting hypoxiainducible factor 1 and 2 for cancer therapy. Yonsei Med J 58(3), 489–496. https://doi.
org/10.3349/ymj.2017.58.3.489 [PubMed PMID: 28332352; PMCID: 5368132].

